Gastric Ulcers - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Gastric Ulcers - Pipeline Review, H2 2016

Gastric Ulcers - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Gastric Ulcers - Pipeline Review, H2 2016
Published Sep 14, 2016
43 pages — Published Sep 14, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Gastric Ulcers - Pipeline Review, H2 2016, provides an overview of the Gastric Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastric Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastric Ulcers
- The report reviews pipeline therapeutics for Gastric Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Gastric Ulcers therapeutics and enlists all their major and minor projects
- The report assesses Gastric Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Gastric Ulcers


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gastric Ulcers
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastric Ulcers pipeline depth and focus of Indication therapeutics
-

  
Source:
Document ID
GMDHC8458IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Gastric Ulcers Overview61
Therapeutics Development71
  Pipeline Products for Gastric Ulcers Overview71
Gastric Ulcers Therapeutics under Development by Companies81
Gastric Ulcers Pipeline Products Glance92
  Clinical Stage Products91
  Early Stage Products101
Gastric Ulcers Products under Development by Companies111
Gastric Ulcers Companies Involved in Therapeutics Development125
  Ache Laboratorios Farmaceuticos S/A121
  Astellas Pharma Inc.131
  ChoDang Pharm Co., Ltd.141
  Kukje Pharmaceutical Industry Co., Ltd.151
  XuanZhu Pharma Co., Ltd.161
Gastric Ulcers Therapeutics Assessment178
  Assessment by Monotherapy Products171
  Assessment by Combination Products181
  Assessment by Target192
  Assessment by Mechanism of Action212
  Assessment by Route of Administration231
  Assessment by Molecule Type241
Drug Profiles257
  (ecabet + ranitidine) Drug Profile251
  anaprazole sodium Drug Profile261
  ASP-6537 Drug Profile271
  KJ-14001 Drug Profile281
  PDI-39 Drug Profile291
  PMKS-005 Drug Profile301
  Small Molecules for Gastric Ulcers Drug Profile311
Gastric Ulcers Dormant Projects321
Gastric Ulcers Discontinued Products331
Gastric Ulcers Product Development Milestones348
  Featured News &Press Releases341
    Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies341
    Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck351
    Jan 07, 2010: AstraZeneca Reaches Agreements with Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations351
    Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy351
    Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck &Co., Inc.361
    Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)371
    Jun 01, 2007: AstraZeneca s Prilosec Patents Upheld By Court371
    Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court381
    Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals381
    Oct 23, 2001: Prilosec US litigation391
    May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec391
    May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent391
    Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement391
    Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada401
    Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy402
Appendix422
  Methodology421
  Coverage421
  Secondary Research421
  Primary Research421
  Expert Panel Validation421
  Contact Us421
  Disclaimer431

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Gastric Ulcers - Pipeline Review, H2 2016" Sep 14, 2016. Alacra Store. May 11, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Gastric-Ulcers-Pipeline-Review-H2-2016-2088-16543>
  
APA:
Global Markets Direct - Market Research. (2016). Gastric Ulcers - Pipeline Review, H2 2016 Sep 14, 2016. New York, NY: Alacra Store. Retrieved May 11, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Gastric-Ulcers-Pipeline-Review-H2-2016-2088-16543>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.